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REVIEW
Abstract: Trospium chloride is a quaternary ammonium compound, which is a competitive
antagonist at muscarinic cholinergic receptors. Preclinical studies using porcine and human
detrusor muscle strips demonstrated that trospium chloride was many-fold more potent than
oxybutynin and tolterodine in inhibiting contractile responses to carbachol and electrical
stimulation. The drug is poorly bioavailable orally (< 10%) and food reduces absorption by
70%– 80%. It is predominantly eliminated renally as unchanged compound. Trospium chloride,
dosed 20 mg twice daily, is significantly superior to placebo in improving cystometric
parameters, reducing urinary frequency, reducing incontinence episodes, and increasing urine
volume per micturition. In active-controlled trials, trospium chloride was at least equivalent
to immediate-release formulations of oxybutynin and tolterodine in efficacy and tolerability.
The most problematic adverse effects of trospium chloride are the anticholinergic effects of
dry mouth and constipation. Comparative efficacy/tolerability data with long-acting
formulations of oxybutynin and tolterodine as well as other anticholinergics such as solifenacin
and darifenacin are not available. On the basis of available data, trospium chloride does not
appear to be a substantial advance upon existing anticholinergics in the management of urge
urinary incontinence.
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Introduction
Urge urinary incontinence (UUI), the most frequent type of urinary incontinence
(UI), has as typical symptoms incontinence associated with urinary frequency (> 8
micturitions/day) and urgency (sudden, strong desire to urinate). Nighttime frequency
(nocturia) and nocturnal incontinence (enuresis) disrupt sleep. Although the etiology
is known in some cases (eg, neurologic diseases such as stroke, Parkinson’s disease,
multiple sclerosis, or spinal cord injury or bladder outlet obstruction due to benign
prostatic hyperplasia or prostate cancer), in most cases the cause is unknown. UUI
and stress UI frequently coexist as mixed UI (Rovner et al 2002).
The most effective agents in suppressing inappropriate bladder contractions,
enhancing bladder storage, and relieving UUI signs and symptoms are the
anticholinergic/antispasmodic drugs (Rovner et al 2002; Herbison et al 2003),
primarily oxybutynin and tolterodine. Other agents, such as tricyclic antidepressants,
propantheline, dicyclomine, scopolamine, and flavoxate, are less effective, no safer,
or have been inadequately studied and are generally not recommended (Rovner et al
2002). Propiverine is an anticholinergic also used in managing UUI but it is not
available in many countries.
Unfortunately, even oxybutynin and tolterodine are only moderately effective in
UUI (Herbison et al 2003), and their systemic (non-urinary tract) anticholinergic
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effects are bothersome, compromise adherence, and may
limit efficacy by limiting dose escalation. The search for a
“uroselective” anticholinergic agent has been intense within
the pharmaceutical industry.
The purpose of this paper is to profile trospium chloride.
Trospium chloride has been available for many years in
Europe, manufactured by Madaus AG (Cologne, Germany)
under the tradename Spasmo-lyt
® and is also available as
Uroplex
® and SpasmoUrgenin
®. This agent has recently
been approved by the US Food and Drug Administration
(FDA) for the treatment of overactive bladder (symptoms
of urinary frequency, urgency, and UUI) under the tradename
Sanctura® (Odyssey Pharmaceuticals, East Hanover NJ and
Indevus Pharmaceuticals, Lexington, MA, USA).
A MEDLINE/PUBMED search was conducted to
identify pertinent articles in the English language. Additional
references were obtained from the bibliographies of these
articles. In addition, proceedings of the Incontinence Society,
European Association of Urology, American Urological
Association, and American College of Obstetrics and
Gynecology meetings were reviewed for relevant abstracts.
Data over the time period of 1966 through June 2004 were
reviewed.
Chemistry
Trospium chloride (Figure 1), also known as azonia-3-α-
benziloyloxy-8-spiro-1´-pyrrolidinium chloride, has the
molecular formula C25H30NO3Cl, and a molecular weight
of 427.97. Its chemical name is spiro[8-azoniabicyclo-
[3,2,1]octane-8,1´-pyrrolidinium]-3-[(hydroxydiphenyl-
acetyl)-oxy]chloride(1α,3β,5α)-(9CI). Solubility in water
exceeds 50 mg per mL at room temperature while in light
mineral oil it is 9.2 × 10
–3 mg/mL (Langguth et al 1997). Its
log partition coefficient between n-octanol and buffer at
pH 7.4 is –1.22 (Langguth et al 1997). Synthesis and
pharmacological activity of this compound were first
described in 1966 (German language literature).
Pharmacodynamics
Ex vivo studies
Ex vivo studies have evaluated the effect of trospium
chloride on the activity of porcine and human detrusor
muscle strips. Parameters studied included EC50 (bath
concentration inducing 50% reversion of carbachol-induced
tension), Rmax (% relaxation at final drug concentration in
bath), IC50 (bath concentration causing 50% inhibition of
maximum contractile response to electrical field
stimulation), and MI (% inhibition of contraction amplitude
at final drug concentration in bath). For porcine tissue,
trospium chloride was significantly more potent than
oxybutynin (EC50 values of 0.006 and 25 µmol/L and Rmax
values of 100 [at 0.1 µmol/L] and 76.2 ± 8%, respectively).
Corresponding values for EC50 and Rmax in human tissue
were 0.003 and 10 µmol/L and 86 ± 13 (at 0.1 µmol/L) and
79 ± 20% (both tissues, p < 0.05) (Uckert et al 1998). In
human tissue, EC50 and Rmax values for trospium chloride,
oxybutynin, and tolterodine were 0.003, 10, and ≤ 1.0 µmol/L,
respectively and 86 ± 13, 50 ± 7, and 70 ± 8%, respectively.
Corresponding IC50 and MI values were 0.05, 10, and
> 10 µmol/L and 80 ± 17, 53 ± 7, and 40 ± 16% (trospium
chloride vs comparators, p < 0.05). In the carbachol and
electrical field stimulation protocols, trospium chloride
produced significant changes from control at all tested
bath concentrations (1, 0.1, 0.01, 0.001, 0.0001, and
0.00001 µmol/L) (Uckert et al 2000). The effects of trospium
chloride were dose-dependent in both ex vivo studies
(Uckert et al 1998, 2000).
In vivo (animal) studies
The effect of trospium chloride on gastrointestinal (GI)
motility in dogs was studied after single 0.1 and 0.5 mg/kg
intravenous (IV) doses. At the 0.5 mg/kg dose level,
complete inhibition of gastric and intestinal motor activity
occurred for up to 0.5 h post-dose, the gastric and jejunal
motility indices (MoI) were substantially reduced, and
colonic contractions and the colonic MoI fell for 2.5 h post
dose (Hatchet et al 1986).
In vivo (human) studies
In a placebo-controlled, crossover, double-blind trial
conducted in 12 healthy human volunteers, the effect of
trospium chloride on 24-h jejunal motility was evaluated.
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Figure 1 Chemical structure of trospium chloride.Therapeutics and Clinical Risk Management 2005:1(2) 159
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Trospium chloride 15 mg orally thrice daily significantly
prolonged the duration of irregular contractile activity after
meals (from mean 324 to 368 min, p < 0.02) and decreased
its contraction frequency (from 2.24 to 1.08/min, p < 0.001)
and amplitude (from 26.5 to 20.3 mm Hg, p < 0.001). In the
fasting state, the cycle length of the migrating motor
complex was significantly prolonged (from 77 to 116 min,
p < 0.01), due primarily to an extended phase I (motor
quiescence) (from 42 to 78 min, p < 0.025). Phase III was
significantly shortened (from 7.3 to 3.8 min, p < 0.005), and
showed a slower aboral migration velocity (from 8.4 to
4.7 cm/min, p < 0.005). Clustered contractions were
significantly less frequent during postprandial (from 42 to
14 per 24 h, p < 0.01) and fasting periods (from 11 to 4 per
24 h, p < 0.01). Runs of clustered contractions were
abolished by the drug. In summary, trospium chloride
significantly reduced jejunal motor activity in healthy
volunteers (Schmidt et al 1994).
The effects of single 0.2, 0.5, 1, and 1.5 mg IV doses of
trospium chloride on gallbladder contractility were evaluated
in 6 female volunteers using a double-blind, crossover
design. Trospium chloride produced a dose-dependent
inhibition of gallbladder contraction induced by a fat
stimulus and measured using sodium iopodate (p < 0.0001).
The two highest doses virtually abolished contractility
(Matzkies et al 1992). Nine volunteers participated in a
randomized, crossover, placebo-controlled trial evaluating
the effect of single IV doses of placebo, 1.2 mg trospium
chloride, and 5 mg biperiden on esophageal motility.
Trospium chloride significantly reduced the amplitude of
primary peristaltic pressure waves (from mean 67 mm Hg
on placebo to 17 mm Hg, p < 0.01) but not their duration.
The frequency of failed primary peristalsis was significantly
increased by the drug (from 0 on placebo to 10%, p < 0.05)
(unit = % of 120 water swallows). The percentage of
secondary contractions elicited by air distension was
significantly reduced by the drug (from 95% on placebo to
60%, p < 0.01). Trospium chloride also significantly
increased the latency to onset of secondary contractions
(from 7 s on placebo to 11 s, p < 0.05) and reduced their
amplitude (from 65 mm Hg on placebo to 25 mm Hg,
p < 0.01). The effects of trospium chloride were statistically
indistinguishable from those of biperiden in all comparisons.
Lastly, trospium chloride had no effect on esophageal evoked
potentials. In summary, trospium chloride impairs
esophageal motility (Pehl et al 1998).
Lastly, the effect of trospium chloride on GI motility
was evaluated in 33 healthy volunteers participating in a
double-blind, crossover, placebo-controlled trial
(gallbladder N = 11, gastric emptying N = 12, gasto-
esophageal reflux and orocecal transit time N = 10). The 4
treatments were placebo and trospium chloride 10, 15, and
20 mg orally at 0600, 1400, and 2200 the day prior to study
and at 0600 on the day of the study. Gallbladder ejection
fractions were significantly reduced by 10 and 20 mg
doses compared with placebo (p < 0.025 and p < 0.01,
respectively), while the effects of the 10 and 20 mg doses
were not significantly different. Gastric emptying was
significantly delayed by the 15 mg dose compared with
placebo (p < 0.02, no change in volume suggests an
antisecretory response to the drug). The fractional time of
esophageal pH below 4 as a percentage of the 24-h study
period was significantly increased by the 15-mg dose
compared with placebo (p < 0.05), as was the orocecal transit
time (p < 0.001) (Pfeiffer et al 1993).
Pharmacokinetics
Healthy volunteers
The pharmacokinetic parameters of trospium chloride have
been extensively reviewed recently (Guay 2003). Table 1
illustrates mean data after drug administration by the oral
and IV routes. Trospium chloride is absorbed slowly after
Table 1 Mean (± SD) pharmacokinetic parameters of trospium chloride after administration by the intravenous and oral routes
(after Guay 2003)
Dose Cmax tmax AUC t½ CL
Population N (mg) Route Frequency (mg/L) (h) (mg/L·h) (h) (mL/min)
Healthy younger men 6 0.5 IV 1 dose ND ND 7.0 ± 2.2 1.6 ± 0.6 1405 ± 830a
807 ± 391
b
Healthy elderly men 18 20 PO 1 dose 1.4 ± 88%
c 3.5 ± 77%
c 14.0 ± 79%
c 10.2 ± 47%
c ND
20 PO q12 h × 9 doses 1.9 ± 47%c 3.2 ± 71%c 15.0 ± 38%c 12.7 ± 32%c ND
a Total body clearance.
b Renal clearance.
c Percentage coefficient of variation.
Abbreviations: AUC, area under the plasma concentration-versus-time curve; CL, clearance; Cmax, peak plasma concentration; d, days; IV, intravenous; ND, not done;
PO, oral; q12h, every 12 hours; tmax, time to Cmax; t ½, terminal disposition half-life.Therapeutics and Clinical Risk Management 2005:1(2) 160
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oral dosing, with mean times to peak plasma concentration
of 5–6 h in healthy young volunteers and 3.5 h in healthy
elderly volunteers. Using urinary excretion data, the
mean ± SD oral bioavailability is 2.91 ± 0.90% (using
trospium chloride data only) and 3.25 ± 1.02% (using total
compound data). Mean (range) absolute bioavailability of a
20 mg dose based on serum concentration data, is 9.6%
(4.0%–16.1%) (Anonymous 2004). Food reduces oral drug
bioavailability by 70%–80%. Absorption after single
intravesical (into the bladder) doses of 15 and 30 mg is
essentially negligible.
Studies have been done using animal models to evaluate
the process of absorption of trospium chloride and methods
to augment it. Absorption of the drug across the intestinal
epithelium is complex, involving P-glycoprotein-mediated
secretion and saturable binding to intestinal mucus
(Langguth et al 1997). Limited permeability across the
epithelial cell layer accounts for the low bioavailability. Use
of water/oil microemulsions or cyclodextrin did not enhance,
and actually reduced, oral bioavailability (Langguth et al
1997). However, oral bioavailability was enhanced by ion
pairing using N-alkylsulfates (6- or 7-carbon chain is
optimal) or N-alkylsulfonates (7- or 9-carbon chain is
optimal) (Langguth et al 1997). In addition, ion pairing using
nonylsulfonate and heptylsulfonate may allow use of a
transdermal formulation (transepidermal flux is increased
by 7.1 ± 5.7-fold and 13.5 ± 23.0-fold, respectively, over
trospium chloride alone) (Langguth et al 1987).
Trospium chloride is 50%–85% plasma protein bound.
The mean ± SD apparent volume of distribution is
395 ± 140 L (Anonymous 2004). There are no published data
regarding the penetration of the drug into the central nervous
system. Renal excretion accounts for approximately 70%
of drug clearance. Approximately 80%, 10%, and < 5% of
urinary excretion is accounted for by parent compound,
spiroalcohol metabolite, and hydrolysis/oxidation products,
respectively. Cumulative 48-h urinary excretion after a single
0.5 mg IV dose was 278 ± 59 µg of parent compound and
10 ± 4 µg of the spiroalcohol metabolite (spiroalcohol
accounts for a mean of 7.1% of total urinary excretion, range
3.2%–10.9%). Corresponding values after a single oral
10 mg dose were 158 ± 43 µg and 16 ± 12 µg (spiroalcohol
accounts for a mean 15.8% of total urinary excretion, range
3.4%–30.4%). Renal clearance is 4-fold higher than
creatinine clearance, indicating that filtration and secretion
are involved (Anonymous 2004). Terminal disposition half-
life (t1/2) is approximately 10–12 h (Anonymous 2004).
Trospium chloride exhibits dose-independence over the
single dose range of 20–60 mg (measured by area under the
serum concentration-versus-time curve [AUC] data) and
dose-dependence when measured by peak concentration
[Cmax] data (3-fold increase when doubling from 20 to 40 mg
and 4-fold increase when tripling from 20 to 60 mg)
(Anonymous 2004). Of interest, there appears to be circadian
variability in trospium chloride pharmacokinetics, with a
decrease in Cmax of up to 59% and AUC of up to 33% for
evening relative to morning dosing (Anonymous 2004). The
mean accumulation factor for a 20 mg twice daily oral
regimen is 1.1 (90% CI 0.85–1.35).
Special populations
Age does not appear to significantly affect trospium chloride
pharmacokinetics although actual data were not presented
in the source document (Anonymous 2004). Conflicting
results have been noted in studies evaluating the effect of
gender on the pharmacokinetics of trospium chloride. After
administration of a single oral 40 mg dose in 16 elderly
subjects, AUC was 45% lower in females compared with
males. In contrast, after 20 mg twice daily administration
for 4 days in 12 elderly patients, Cmax and AUC were 68%
and 26% higher, respectively, in females versus males
(Anonymous 2004).
Trospium chloride Cmax is increased by means of 12%
and 63% in subjects with mild (Child-Pugh class A) and
moderate hepatic impairment (Child-Pugh class B),
respectively, compared with healthy subjects. However,
AUC is similar in the three groups. No data are available
regarding the effect of severe hepatic impairment (Child-
Pugh class C) (Anonymous 2004). Renal impairment
significantly alters trospium chloride pharmacokinetics.
Patients with severe renal impairment (creatinine clearance
< 30 mL/min) demonstrate a 4.5-fold increase in AUC,
2-fold increase in Cmax, and a 2- to 3-fold increase in t1/2
compared with healthy volunteers. In this patient population,
a 50% reduction in daily dose is recommended (Anonymous
2004).
Efficacy
Table 2 illustrates available English language efficacy/
tolerability studies of trospium chloride in UUI, in which
placebo and active control (oxybutynin, tolterodine) groups
were used (Stohrer et al 1991; Madersbacher et al 1995;
Junemann et al 1999; Cardozo et al 2000; Hofner et al 2000;Therapeutics and Clinical Risk Management 2005:1(2) 161
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Table 2 Clinical efficacy/tolerability studies of trospium chloride in the management of urge urinary incontinence
Duration
Reference  (wk) Regimens N Results (compared with baseline)
Stohrer 3 TC 20 mg bid 27 All patients had detrusor hyperreflexia due to spinal cord injury. TC significantly increased
et al 1991 Plac bid 28 maximum cystometric capacity (median change 120 mL vs placebo 0 mL) (p < 0.001) and
bladder compliance (10 vs 1 mL/cm H2O, p < 0.001), and reduced maximum detrusor
pressure (–35.0 vs –2.5 cm H2O, p < 0.001). No significant intergroup differences were noted
with maximum urine flow rate or residual urine volume (p = 0.8 for each). In the 6 patients
with partial sensation who could complete a study diary, micturition intervals increased by
approximately 30% with TC. Spontaneously reported AE occurred in 1 TC patient
(constipation) and 5 Plac patients (nausea, dry mouth, tiredness plus decreased exercise
capacity, constipation and nervousness plus constipation).
Cardozo 3–3.5 TC 20 mg bid 104 The study was stopped early as interim analysis demonstrated superiority of TC over Plac. By
et al 2000 Plac bid 104 intent-to-treat analysis, the treatment effect of TC (TC effect-Plac effect) was +22.0 mL for
maximum cystometric capacity (p = 0.0054), +45.0 mL for volume at first unstable contraction
(p = 0.0015), and +7.0 mL for volume at maximum contraction (p = 0.0113). The 2 treatments
were not significantly different with respect to effect on bladder compliance, residual urine
volume, or maximum detrusor pressure at first unstable contraction. Investigators assessed
26 and 30 TC patients as markedly and slightly improved, respectively, while corresponding
figures for Plac patients were 17 and 26 (patient assessments were similar). In a subgroup
analysis of patients with bladder capacity ≥ 350 mL, the treatment effect of TC was again
significant for maximum cystometric capacity (+58 mL, p < 0.001) and volume at first unstable
contraction (+90 mL, p < 0.001). AE occurred in 68% TC and 62% Plac patients. Xerostomia
was the most frequent AE (43 TC and 18 Plac patients) followed by GI disorders. Dizziness
occurred in 11 TC and 15 Plac, and headache in 25 TC and 36 Plac patients. Drug acceptability
by the patient was noted as very good/good in 37/50% of TC and 29/40% of Plac patients (no
statistical results for AE were available).
Frohlich 3 TC 20 mg bid 314 By intent-to-treat analysis, the treatment effect of TC over Plac was significant for maximum
et al 2002 Plac bid 203 cystometric capacity (+52 mL, p < 0.0001), volume at first unstable contraction (+48 mL,
p = 0.0001) and volume at maximum contraction (+40 mL, p = 0.0042). Nonsignificant
treatment effects were noted for maximum detrusor pressure at first unstable contraction
and residual urine volume. Per protocol analysis gave similar results. Clinical cure or marked
improvement (per patient self-assessment) occurred in 47.9% and 19.7% of TC and Plac
patients, respectively. The distributions of clinical responses (per patient self-assessment) were
significantly different in the 2 groups (p < 0.0001, more cure/markedly improved with TC and
more slightly improved/no improvement/worsened with Plac). The investigator assessment was
similar to that of the patients. ≥ 1 AE occurred in 35.7% of TC and 38.9% of Plac patients. The
most frequent AE were GI disorders (TC 21.7%, Plac 18.7%) and xerostomia was the most
frequent individual AE (TC 14.0%, Plac 8.4%; p = 0.052). CNS disorders (mostly headache)
occurred in 11.1% of TC and 17.7% of Plac patients (p = 0.033). The global judgments of
tolerability by investigators and patients were similar (between treatments and between each
other).
Junemann 3 TC 40 mg qd 56 The treatment effects of TC 40 mg qd and 40 mg bid over Plac were similar for maximum
and Fusgen TC 40 mg bid 56 cystometric capacity (+45.3 and +61.4 mL, respectively; p = 0.0006 vs Plac for both), volume at
1999 Plac 58 first unstable contraction (+53.5 and +75.2 mL, p = 0.0333 vs Plac for both), and volume at
maximum contraction (+45.2 and +77.0 mL, p = 0.0015 vs Plac for both). Treatment effects for
volume at first desire to urinate and residual urine volume were not significant. No data were
available regarding the statistical comparison of the 2 active treatments. AE frequency was
dose-dependent (Plac 28.3%, TC 40 mg qd 51%, TC 40 mg bid 64%) and were mainly the
expected anticholinergic effects.
Hofner et al 52 TC 20 mg bid 177 Per protocol analysis revealed statistically-indistinguishable treatment effects for the 2 drugs
2000 Oxy 5 mg bid 58 while both drugs produced significant effects compared with baseline (maximum cystometric
capacity: +115 mL for TC and +119 mL for Oxy; volume at first unstable contraction: +66 mL
for TC and +49 mL for Oxy; volume at first desire to urinate: +86 mL for TC and +75 mL for
Oxy). Frequency fell 31% on TC and 34% on Oxy. The number of incontinent episodes fell by
approximately 1 per day with both drugs.AE occurred in 64.8% of TC and 76.7% of Oxy
recipients (p < 0.01). Treatment-emergent AE (ie, those judged to be possibly, probably, or
continued overleafTherapeutics and Clinical Risk Management 2005:1(2) 162
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Table 2 continued
Duration
Reference  (wk) Regimens N Results (compared with baseline)
definitely drug-related) occurred in 47.9% of TC and 58.9% of Oxy recipients (p = 0.02). GI AE
occurred in 39% of TC and 51% of Oxy recipients (p = 0.02), while xerostomia occurred in
33% of TC and 50% of Oxy recipients (p < 0.01). Tolerability of treatment was judged very good
by 63% of TC and 42% of Oxy recipients (p = 0.004). The investigator assessment of
tolerability was similar to that of the patients, favoring TC (p = 0.008).
Madersbacher 2 TC 20 mg bid 88
a All patients had detrusor hyperreflexia due to spinal cord injury. The treatment effects of the
et al 1995 Oxy 5 mg tid 2 drugs were statistically indistinguishable from each other but both agents produced
significant effects (p < 0.001) compared with baseline (maximum cystometric capacity; +97 mL
for TC and +163 mL for Oxy; maximum voiding detrusor pressure: –35.4 cm H2O for TC and
–38 cm H2O for Oxy; bladder compliance: +17 mL/cm H2O for TC and +22.6 mL/cm H2O for
Oxy; residual urine volume: +76.5 mL for TC and +114.1 mL for Oxy). The frequency of
hyperreflexive waves fell over time in both groups in a similar pattern (p = 0.16).Premature
study withdrawal occurred in 16% of Oxy and 6% of TC patients and occurred earlier in the
Oxy compared with TC groups (after means of 7 and 14 days on treatment, respectively).
However the reasons for withdrawal were not listed, making interpretation of these data
difficult. The only AE mentioned was xerostomia, which occurred in 54% of TC (4% being
severe) and 56% of Oxy (23% being severe) patients.
Junemann 3 TC 20 mg bid 57 The change from baseline in number of frequency episodes over 24 h was –3.4, –2.6, and –1.9,
and Tolt 2 mg bid 63 for TC, Tolt, and Plac recipients (p = NS for Tolt vs Plac and p = 0.01 for TC vs Plac but no data
Al-Shukri Plac bid 60 for TC vs Tolt). AE occurred in 34, 32, and 15% of TC, Tolt, and Plac recipients, respectively,
2000 with corresponding rates of mild xerostomia of 85, 84, and 42% in those who had that AE.
Zinner 12 TC 20 mg bid 253 By intent-to-treat analysis, at 12 weeks TC was superior to Plac in reducing urinary
et al 2004 Plac bid 256 frequency/24 h (by –2.4 and –1.3 events, p ≤ 0.001), urge incontinence episodes/24 h (by –59
and –44%, p ≤ 0.0001), urge micturitions/24 h (–2.3 and –1.1 events, p ≤ 0.0001), diurnal
micturitions/24 h (–1.9 and –1.0 events, p ≤ 0.0001), nocturnal micturitions/24 h (–0.5 and –0.3
events, p ≤ 0.05) and increasing urine volume/micturition (by +32.1 and +7.7 mL, p ≤ 0.0001).
The superiority of TC over Plac was apparent as early as the week 4 visit. TC also reduced
the impact of incontinence on QOL more than did Plac (measured by Incontinence Impact
Questionnaire; for all patients by –54 and –36 points, p ≤ 0.05; for females by –59 and –36
points, p ≤ 0.05; for males by –33 and –35 points, NS). The subscores significantly improved by
TC were travel, social relationships, and emotional health (all p ≤ 0.05). The results of other
TC were travel, social relationships, and emotional health (all p ≤ 0.05). The results of other
end point analyses demonstrated no significant differences between males and females. The
five commonest AE were dry mouth (TC 22%, Plac 7%), constipation (10% and 4%), headache
(7% and 5%), abdominal pain (3% and 1%), and diarrhea (3% and 5%) (no statistical results
available). Mean increase in heart rate in trospium chloride recipients was 3 beats/minute
compared with placebo.
Anonymous 12 TC 20 mg bid 323 By intent-to-treat analysis, TC was superior to Plac in reducing urinary frequency/24 h (by
(Study 2)  Plac bid 325 –2.7 and –1.8 events, p < 0.001) and urge incontinence episodes/week (by –16.1 and –12.1
2004 events, p < 0.001) and increasing urine volume/micturition (by +35.6 and +9.4 mL, p < 0.001).
The superiority of TC over Plac was apparent as early as the week 4 visit. Pooled AE data
(Zinner et al 2004 + this study) are available in Table 3. Mean increase in heart rate in
trospium chloride recipients was 4 beats/minute compared with placebo.
a The number in each group was not given. 95 patients enrolled but data were evaluated in only 88 patients. Randomization was 1:1, so it was likely that
approximately equal numbers were in the two groups.
Abbreviations: TC, trospium chloride; Plac, placebo; AE, adverse event; bid, twice daily; GI, gastrointestinal; CNS, central nervous system; qd, once daily; Oxy,
oxybutynin immediate-release; Tolt, tolterodine immediate-release; tid, three times daily; NS, not significant; QOL, quality-of-life.
Junemann et al 2000; Frohlich et al 2002; Anonymous 2004;
Zinner et al 2004). These were randomized, double-blind,
and parallel-group in design. The two studies used for US
licensing purposes were the two studies described in the
product information sheet (Anonymous 2004), one of which
has been recently published (Zinner et al 2004).
The majority of published clinical trials have emphasized
cystometric end points, not clinical ones, with the exception
of the two trials described in the product information sheet
(one remains unpublished). Trospium chloride is rather
unique in this regard, and the paucity of clinical outcome
data does make evaluation of this agent difficult, especiallyTherapeutics and Clinical Risk Management 2005:1(2) 163
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in comparison with established anticholinergics. Trospium
chloride has been uniformly superior to placebo and
equivalent to immediate-release formulations of oxybutynin
and tolterodine. No data are available regarding comparative
efficacy with the newer long-acting formulations of
oxybutynin and tolterodine, as well as solifenacin and
darifenacin. Although statistically superior to placebo, the
absolute differences between trospium chloride and placebo
are not substantial and may call into question the clinical
importance of such differences.
Safety
Table 2 illustrates the safety data from the individual
placebo- and active-controlled English language clinical
trials of trospium chloride (Stohrer et al 1991; Madersbacher
et al 1995; Junemann et al 1999; Cardozo et al 2000; Hofner
et al 2000; Junemann et al 2000; Frohlich et al 2002;
Anonymous 2004; Zinner et al 2004). Table 3 illustrates
the product information sheet data, which cite pooled results
from two studies (Anonymous 2004; Zinner et al 2004). As
would be expected, most adverse events are an extension of
the drug’s anticholinergic properties. An interesting finding
from these latter data is the increased frequency of
anticholinergic adverse events in those subjects 75 years of
age and older (15% of trospium chloride recipients were in
this age stratum) compared with younger subjects. This is
felt to be pharmacodynamic in nature (ie, increased
sensitivity) and not pharmacokinetic (Anonymous 2004).
A double-blind, randomized, placebo-controlled study
in 29 healthy volunteers was performed to assess the
maximum tolerated single oral dose of trospium chloride.
The doses evaluated were 20, 40, 80, 120, 180, 240, and
360 mg. At each dose level, 9 subjects were randomized to
active drug and 3 to placebo (exception: at 360 mg, the
corresponding numbers were 8 and 2). There were
essentially no inter-treatment differences (drug vs placebo)
at doses of 120 mg and less. Anticholinergic effects of
increasing intensity occurred at a dose of 180 mg and above
(pupillary dilatation, decreased salivary flow, increased heart
rate). With the 360 mg dose, vital signs were unchanged but
subjects found the experience to be “quite unpleasant”.
Pupillary effects were not seen until doses were greater than
or equal to 180 mg. These three doses produced a long-
lasting dilatation significantly different from that of placebo,
but dose-dependence was not noted. A similar threshold was
found for the hyposalivation effect and, in contrast to the
pupillary effect, dose-dependence was noted. A similar
threshold was found for the tachycardic effect and, like
the pupillary effect, dose-dependence was not noted.
Tachycardia appeared at 4 to 8 h post-dosing and disappeared
by 12 h post-dosing. No significant effect on blood pressure
was noted at any dose. No electrocardiographic effects
occurred at any dose except a 10 to 40 ms reduction in the
QT interval due to the tachycardia. Of recorded adverse
events, only the frequency and intensity of xerostomia was
dose-dependent. At lower doses, xerostomia was of mild
intensity while after the 240 and 360 mg doses it was of
moderate to severe intensity (Breuel et al 1993).
The effect of trospium chloride on QT interval was
evaluated in a single-blind, randomized, placebo- and active
(moxifloxacin)-controlled trial in 170 healthy volunteers.
Subjects were randomized to five days of placebo,
moxifloxacin 400 mg once daily, or various doses of
trospium chloride (ranging from 20 to 100 mg twice daily).
The QT interval was evaluated over a 24 h period at steady
state. The QT interval was not affected by any dose of
trospium chloride while moxifloxacin had the expected
effect (mean Fredericia-corrected prolongation of 6.4 ms).
Dose-dependent tachycardia was seen in trospium chloride
recipients, with mean increases of 9.1 and 18.0 beats/minute
in the 20 and 100 mg dose groups, respectively (Anonymous
2004).
In the gallbladder contractility study reviewed
previously, xerostomia did not occur with the single 0.2 and
0.5 mg IV doses of trospium chloride but did occur in 3 of
Table 3 Pooled adverse event data (percentage) from the two
placebo-controlled trospium chloride (20 mg twice daily) trials
described in the package insert (Anonymous 2004)a
Event Placebo Trospium chloride
N 590 591
Gastrointestinal
Dry mouth 5.8 20.1
Constipation (new onset) 4.6 9.6
Upper abdominal pain 1.2 1.5
Worsened constipation 0.8 1.4
Dyspepsia 0.3 1.2
Flatulence 0.8 1.2
Nervous system
Headache 2.0 4.2
General
Fatigue 1.4 1.9
Renal/Urinary
Urinary retention 0.3 1.2
Eye
Dry eye NOS 0.3 1.2
a Those events judged to be at least possibly related to treatment with trospium
chloride, reported in ≥ 1% of trospium chloride recipients, and more frequent in
trospium chloride than placebo recipients.
Abbreviations: NOS, not otherwise specified.Therapeutics and Clinical Risk Management 2005:1(2) 164
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6 subjects after the single 1.0 and 1.5 mg IV doses. At these
latter doses, a transient dose-dependent tachycardia also
occurred, reaching a peak at 0.25 h post-dosing (Matzkies
et al 1992). Two case reports have also documented the
potential for significant tachycardia after IV trospium
chloride (Hasselkus 1998; Pfeiffer et al 1999). In one report,
IV administration of 2 mg as premedication for endoscopy
in 24 patients caused mean heart rate to rise from 81 to 125
beats/min within 1 min after dosing (Hasselkus 1998). In
the other report, 31 patients again received the drug as
premedication for endoscopy. In these patients, 1.2 mg of
IV trospium chloride produced a rise in heart rate of
approximately 14 beats/minute at 5, 10, and 15 minutes post-
dosing (Pfeiffer et al 1999).
Two electroencephalographic (EEG) studies have been
conducted to quantitate the central nervous system effects
of trospium chloride, oxybutynin, tolterodine, and placebo
in healthy volunteers (Pietzko et al 1994; Todorova et al
2001). The first study was a randomized, crossover design
evaluating single doses of trospium chloride (1.2 mg IV,
45 mg oral) and oxybutynin (20 mg oral) in 12 subjects. Ten
of these 12 subjects were also evaluated in a no drug state
but this was not a placebo phase within the crossover design.
No significant EEG effects were associated with trospium
chloride by either route of administration. Oxybutynin
caused a significant reduction in alpha and beta 1 activity
(with eyes open, eyes closed, during reaction time testing).
Heart rate significantly rose after IV trospium chloride
administration, peaking at 20 min post-dosing with a 60%
increase. Heart rate returned to baseline by 4 h post-dosing.
No significant heart rate effect was noted with oral trospium
chloride while oral oxybutynin caused a significant
reduction, which peaked at 3 h post-dosing and did not return
to baseline within the 4 h evaluation period. Adverse events
included xerostomia (in 1, 2, and 1 trospium chloride oral,
trospium chloride IV, and oxybutynin recipients,
respectively), tachycardia (in 2 trospium chloride IV
recipients), and headache (in 1 trospium chloride IV
recipient; moderate to severe, occurring at 7 h post-dosing
and lasting 3 h, requiring no treatment) (Pietzko et al 1994).
The second study was a randomized, single blind design
evaluating trospium chloride (15 mg thrice daily),
oxybutynin (5 mg thrice daily), tolterodine (2 mg twice
daily), and placebo, with each treatment lasting 1 day. Each
of the sixty-four subjects was randomized to 1 of the 4
treatment groups. Trospium chloride and tolterodine did not
induce any power change in 5 of 6 EEG frequency bands
(delta, alpha 1, alpha 2, beta 1, beta 2) and caused isolated
reductions in power of the theta band. In contrast,
oxybutynin significantly reduced EEG power in 4 bands:
theta, alpha 1, alpha 2, beta 1. Tolerability was rated as “very
good” by 81.3, 62.5, 56.3, and 50% of placebo, tolterodine,
trospium chloride, and oxybutynin recipients, respectively.
Fifty-seven adverse events (36 being possibly drug-related)
occurred in 30 subjects: 4 with placebo (maximum of
1/subject), 14 with tolterodine (3 had > 1 event), 15 with
trospium chloride (4 had > 1 event), and 24 with oxybutynin
(8 had > 1 event). In terms of central nervous system events,
3 events occurred in 3 placebo recipients, 5 events in 4
tolterodine recipients, 11 events in 8 trospium chloride
recipients, and 17 events in 8 oxybutynin recipients. The
events in trospium chloride recipients included headache in
5 subjects, tiredness in 2 subjects, and impaired
concentration, restless sleep, cold sensation, and single
myoclonus in 1 subject each (Todorova et al 2001). At the
present time, there are no data to support the hypothesis
that trospium chloride is less neurotoxic than non-quaternary
anticholinergics due to reduced transit across the blood brain
barrier (due to its quaternary amine structure).
Drug–drug interactions
In vitro studies have demonstrated that trospium chloride
exerts negligible effects on cytochrome P450 (CYP)
isozymes 3A4, 1A2, 2E1, 2C19, 2C9, and 2A6 in human
liver microsomes. Although it is a reasonably potent inhibitor
of CYP isozyme 2D6, the inhibition constant (ki) is 1000-
fold higher than the Cmax achievable with the usual oral
regimen. Hence, the likelihood of a clinically-important drug
interaction with CYP isozyme 2D6 substrates and trospium
chloride is very low (Anonymous 2004). However, no formal
studies have been conducted evaluating potential drug–drug
interactions with trospium chloride. Whether drugs actively
secreted in the renal tubules affect trospium chloride
pharmacokinetics (and vice versa) is unknown.
Dosing and administration
The usual dosage regimen is 20 mg orally twice daily. The
drug should be taken at least 1 h before meals or on an empty
stomach. The daily dose should be reduced by 50% in the
presence of severe renal impairment (creatinine clearance
< 30 mL/min), ie, 20 mg once daily at bedtime. In patients
75 years of age and over, dose reduction to 20 mg once
daily should be considered based upon tolerability
(Anonymous 2004).Therapeutics and Clinical Risk Management 2005:1(2) 165
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Conclusion
A major deficiency of the database with trospium chloride
is the relative lack of efficacy/tolerability data in the older
population, especially those over 75 years of age. Subjects
aged 75 years and above constituted only 15% of the FDA
New Drug Application trial database. In this age stratum,
the prevalence of anticholinergic adverse events was higher
compared with younger subjects. In the “real world”,
anticholinergics are prescribed most frequently to older
subjects and it is reasonable to expect that the comorbidities
and polypharmacy characteristic of this population will
enhance drug toxicity. In fact, the majority of anticholinergic
drugs for UUI are considered to be “potentially inappropriate
drugs” for the elderly in the Beers criteria (exceptions:
oxybutynin sustained-release and, by extension, tolterodine
sustained-release) (Fick et al 2003). Based on the adverse
event frequency data from the individual studies and the
product information sheet, trospium chloride would fit the
Beers criteria as a “potentially inappropriate drug” in the
elderly.
Trospium chloride is one of the most recently approved
anticholinergics for management of UUI in the US. Despite
its commercial availability elsewhere for many years, there
are no published comparative data available with the long-
acting topical and oral oxybutynin and oral tolterodine
formulations. The published database on the drug’s
pharmacokinetics and drug interaction potential are similarly
inadequate. In addition, no published quality-of-life or
pharmacoeconomic data are available. In light of available
data, trospium chloride does not appear to be a significant
advance on existing anticholinergics for UUI. The quest for
the magic “uroselective” bullet continues.
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